Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-02-13 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
非公开发行股份上市流通提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from 瑞康医药股份有限公司 regarding the lifting of trading restrictions on shares issued in a previous non-public offering. It details the number of shares becoming freely tradable, the shareholders involved, and the compliance with regulatory requirements. The document includes specific dates, share quantities, and regulatory approvals but does not contain financial statements or detailed financial analysis. It is a notification about share circulation changes rather than a financial report or earnings release. Therefore, it fits the category of Share Issue/Capital Change (SHA), as it concerns the change in share capital availability and listing status of shares.
2018-02-13 Chinese
国金证券股份有限公司关于公司非公开发行限售股份上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Guojin Securities Co., Ltd. regarding the listing and circulation of restricted shares from a non-public issuance by Ruikang Pharmaceutical Co., Ltd. It details the share issuance approvals, lock-up periods, shareholding changes, and compliance with relevant securities regulations. The document is a formal opinion on the share circulation and lock-up release, not a financial report or earnings release. It is a regulatory compliance and verification statement related to share issuance and circulation. This fits best under Regulatory Filings (RNS) as it is a compliance and verification document rather than a financial report or announcement of voting results or capital changes.
2018-02-13 Chinese
关于公司董事、监事和高管计划通过有限合伙企业增持公司股份的进展公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a planned shareholding increase by the company's directors, supervisors, and senior management through a limited partnership. It details the number of shares acquired, the transaction method, and compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion of financial results. The content focuses on insider share transactions by company executives. Therefore, this fits the category of Director's Dealing (DIRS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2018-02-08 Chinese
2017年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a '2017年度业绩快报' which translates to '2017 Annual Performance Express Report' or '2017 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2017, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary, internally audited but not yet audited by an external accounting firm, and may differ from the final annual report. It also includes explanations of the financial performance and changes compared to the previous year. The document length is 1541 characters, which is relatively short and consistent with a brief earnings release rather than a full annual report. There is no indication that this is a full annual report (10-K) or a report publication announcement. The content matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER). FY 2017
2018-01-31 Chinese
国金证券股份有限公司关于公司2017年度定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2017年度定期现场检查报告' which translates to '2017 Annual On-site Inspection Report' by the sponsor Guojin Securities Co., Ltd. for Ruikang Pharmaceutical Co., Ltd. The content focuses on detailed inspection of corporate governance, internal controls, information disclosure, use of raised funds, and compliance with laws and regulations. It includes findings and opinions from the inspection, signatures, and dates. The document is about a regulatory on-site inspection report rather than a full annual report or audit report. It is a standalone audit-related report but not a full audit report of financial statements. Given the nature and content, it fits best under Audit Report / Information (AR). The document length is 4061 characters, which is sufficient to contain substantive content rather than a mere announcement. Therefore, the classification is AR with high confidence. H2 2017
2018-01-15 Chinese
关于深圳证券交易所问询函的回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from 瑞康医药股份有限公司 responding to an inquiry letter from the Shenzhen Stock Exchange regarding a stock increase plan by some directors, supervisors, and senior management through a limited partnership investment vehicle. It includes explanations about the nature of the stock increase plan, management and decision mechanisms of the investment vehicle, risk prevention measures, insider trading controls, and shareholding before and after the increase. The document is a regulatory response to an exchange inquiry, focusing on compliance and disclosure related to insider shareholding and stock increase plans. It does not contain financial statements, earnings data, or annual/interim report content. It is not a report publication announcement since it contains substantive content and explanations. The document fits best under Regulatory Filings (RNS) as it is a compliance and disclosure announcement responding to a regulatory inquiry, not a financial report or other specific filing type.
2018-01-05 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.